Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | -.--% | -.--% | -.--% |
2019 | Roivant Sciences GmbH cancelled the acquisition of substantially all of the assets from PhaseRx, Inc. | CI |
2018 | PhaseRx, Inc. Bankruptcy Case Dismissed | CI |
Performance
1 year | +100.00% | ||
3 years | -98.67% | ||
5 years | -96.55% |
Volumes
marketsBasic data
Highs and lows
Indicators
Sector Comparison - Bio Therapeutic Drugs
Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
---|---|---|---|---|---|---|
-.--% | -.--% | -.--% | +100.00% | 2.34K | ||
+0.17% | +7.41% | +9.15% | +27.46% | 105B | ||
+0.35% | +1.59% | -1.08% | +16.98% | 104B | ||
+1.34% | +4.04% | +5.79% | -0.30% | 22.94B | ||
+0.68% | +6.14% | -11.55% | -13.60% | 22.34B | ||
-2.77% | +2.53% | -7.01% | -26.62% | 19.25B | ||
+4.83% | +6.66% | -37.08% | -31.13% | 17.08B | ||
+0.14% | +3.80% | -9.91% | -36.01% | 16.96B | ||
+0.71% | +2.03% | +7.55% | +44.75% | 14.16B | ||
+1.03% | +4.84% | +40.04% | +6.49% | 12.63B | ||
+1.61% | +3.70% | +320.26% | +242.13% | 8.49B | ||
-0.33% | +0.27% | -24.78% | -34.16% | 8.26B | ||
-2.33% | -4.39% | +6.39% | +40.73% | 7.84B | ||
-0.07% | -0.54% | +0.28% | +29.87% | 7.73B | ||
+6.45% | +10.24% | -49.80% | -68.68% | 7.44B | ||
+0.67% | +8.80% | +5.73% | +30.48% | 7.17B | ||
Average | +0.78% | +3.99% | +15.87% | +20.52% | ||
Weighted average by Cap. | +0.52% | +4.66% | +6.92% | +14.25% |
Historical data
Date | Opening | High | Low | End-of-day | Volume |
---|
Monthly variations
Annual change
2023 | +100.00% | ||
2022 | -50.00% | ||
2021 | -92.59% | ||
2020 | +285.71% | ||
2019 | -75.00% | ||
2018 | -99.28% | ||
2017 | -74.84% | ||
2016 | -69.12% |
- Stock Market
- Equities
- PZRXQ Stock
- Quotes PhaseRx, Inc.